口服deucravacitinib用于治疗不耐治疗的皮肤性红斑狼
Ethan J Matthew1, Kritin K Verma2, Brent Paulger3
1Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.
Cureus
|May 2, 2025
概括
德乌克拉维西替尼 (deucravacitinib) 有效地治疗了一名患有长期耐治疗的光盘性狼 (DL) 的患者. 该疗法在八个月内导致病变完全消失,对类似的病例显示出有前途.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性皮肤性狼和光盘性狼 (DL) 可以耐治疗.
- 既定疗法往往无法为严重病例提供持续的缓解.
研究的目的:
- 报告deucravacitinib在耐火性光盘性狼患者中的疗效.
- 评估deucravacitinib作为皮肤性狼的潜在新型治疗剂.
主要方法:
- 一名66岁的女性患者有25年的抗治疗DL病史,接受了每天6毫克deucravacitinib的治疗.
- 在8个月的时间内,对临床反应进行了监测.
主要成果:
- 活跃的病变在开始使用deucravacitinib后的五个月内消失.
- 在八个月后观察到完全的临床解脱.
- 治疗与先前的损伤部位的炎症后低颜色化有关.
结论:
- 作为TYK2抑制剂的deucravacitinib在患有重症,耐治疗的光盘性狼的患者中表现出显著的疗效.
- 这表明deucravacitinib可能是通过抑制I型干扰素信号传递来治疗皮肤狼的一种有希望的新疗法.
- 需要进一步的纵向研究来证实它在这个患者群体中的有效性.
相关概念视频
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692


